Drug Profile
Research programme: small molecule therapeutics - Infinity/Novartis
Alternative Names: Small molecule therapeutics research programme: Infinity/NovartisLatest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals; Novartis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Dec 2008 Discontinued for Undefined indication in USA (unspecified route)
- 14 Mar 2007 Infinity Pharmaceuticals has recognised a $US4.5 million revenue from delivery of compounds to Novartis under this agreement
- 30 Nov 2004 Early research in Undefined in USA (unspecified route)